Manhattan Scientifics Seed Funded Imagion Biosystems & Owns 64 Million Shares IBX

TV Interview CEO Bob Proulx Explains Cancer Diagnostic

July 25, 2019

Click here to view the printer friendly version of this press release

NEW YORK--Manhattan Scientifics (OTC; QB MHTX) announces its former wholly owned sub Imagion Biosystems (ASX:IBX) Receives A$2 million in R&D Tax Incentives from the Australian Government (ATO).

Bob Proulx, Executive Chairman of Imagion Biosystems, said: “We are very pleased to report to our shareholders that the tax incentive funds have been received and that the rebate came in higher than the A$1.7 million we originally expected. This cash infusion will significantly enhance our ability to advance the development of our ground-breaking diagnostic imaging technology which was recently designated by the U.S. Food and Drug Administration as a ‘Breakthrough Device’”.

TV Interview CEO Bob Proulx Explains Cancer Diagnostic




About Manhattan Scientifics

Manhattan Scientifics Inc. ( is focused on commercialization of disruptive technologies in the nano medicine space.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.